Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 02, 2015 11:53 PM ET

Biotechnology

Company Overview of Algeta ASA

Company Overview

Algeta ASA, an oncology company, focused on developing targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. Its lead product includes radium-223 dichloride, which completed Phase III clinical trial to treat castration-resistant prostate cancer with bone metastases. The company is also developing alpha-emitter thorium-227 that is in the preclinical phase linked to tumor-targeting molecules to form targeted thorium conjugates. It has an agreement with Bayer Pharma AG for the development and commercialization of radium-223 worldwide. The company was formerly known as Anticancer Therapeutic Inventions AS and changed its name to Algeta ASA in 2003. Algeta ASA wa...

Kjelsåsveien 172 A

PO Box 54 Kjelsås

Oslo,  0411

Norway

Founded in 1997

182 Employees

Phone:

47 23 00 79 90

Fax:

47 23 00 79 91

Key Executives for Algeta ASA

Managing Director
Age: 59
Co-Founder and Member of Scientific Advisory Board
Chief Financial Officer
Age: 46
President of Algeta US
Age: 44
Senior Vice President of Quality and Regulatory Affairs
Age: 62
Compensation as of Fiscal Year 2015.

Algeta ASA Key Developments

Algeta ASA Announces Management Changes

Algeta ASA announced that Dr. Ramdahl succeeds company's former CEO Andrew Kay. Thomas Ramdahl has been with Algeta in various leadership roles since 2001, including serving as the CEO until 2009. Thomas Ramdahl reports to Oliver Rittgen, the CEO of Bayer Nordic and the Chairman of the board at the company.

Algeta ASA, Special/Extraordinary Shareholders Meeting, Mar 14, 2014

Algeta ASA, Special/Extraordinary Shareholders Meeting, Mar 14, 2014., at 10:00 Central European Standard Time. Location: Arne Jacobsens Allé 13. Agenda: To consider election of a chairperson and a person to co-sign the minutes; to seek approval of the notice and the agenda; to seek changes to the articles of association; to seek election of a new board of directors; to seek application for de-listing of the shares in Algeta ASA from Oslo Stock Exchange.

Algeta ASA(OB:ALGETA) dropped from Oslo OBX Total Return Index

Algeta ASA will be removed from the Oslo OBX Total Return Index.

Similar Private Companies By Industry

Company Name Region
InstrumeC AS Europe
Cryogenetics AS Europe
Akvaforsk Genetics Center AS Europe
Biosense Laboratories AS Europe
Cgene AS Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Algeta ASA, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.